Exhibit 99.1

Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability

REHOVOT, Israel, and Hoboken, NJ – August 14, 2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three and six months ended June 30, 2024.

“Our strong financial performance is indicative of the successful execution of our growth strategy as we continue to effectively leverage our multiple diverse commercial catalysts, including our six FDA-approved products,” said Amir London, Kamada’s Chief Executive Officer. “With total revenues for the first half of 2024 of $80.2 million, which represents year-over-year growth of 18%, adjusted EBITDA of $16.6 million, up 68% year-over-year and representing a 21% margin of revenues, we achieved the top- and bottom-line profitable growth anticipated in our business. In addition, during the first six months of the year, we generated $15.0 million of cash provided by operating activities, which demonstrates our ability to convert our reported adjusted EBITDA to operational cash flow.”

“Based on our continued strong performance and expectation for a cadence of financial results in the second half of 2024 consistent with those achieved in the first six months of the year, we are reiterating our full-year 2024 revenue guidance of $158 million to $162 million, and our adjusted EBITDA guidance of $28 million to $32 million. Importantly, we continue to pursue compelling new business development opportunities, leveraging our financial strength. These opportunities are expected to support continued growth at double-digit rates beyond 2024,” added Mr. London.

“Patient enrollment continues in our ongoing pivotal Phase 3 InnovAATe clinical trial for the inhaled Alpha-1 Antitrypsin therapy. Last quarter, we filed an IND amendment with the FDA consisting of a revised Statistical Analysis Plan (SAP) and study protocol, which, if approved, may allow for the acceleration of the program. We continue to expect further FDA feedback before the end of this year,” concluded Mr. London.

Financial Highlights for the Three Months Ended June 30, 2024

Financial Highlights for the Six Months Ended June 30, 2024

Balance Sheet Highlights

As of June 30, 2024, the Company had cash, cash equivalents, and short-term investments of $56.5 million, as compared to $55.6 million on December 31, 2023.

Fiscal Year 2024 Guidance

Kamada continues to expect to generate fiscal year 2024 total revenues in the range of $158 million to $162 million, and adjusted EBITDA in the range of $28 million to $32 million, representing double digit top- and bottom-line growth year-over-year.

Conference Call

Kamada management will host an investment community conference call on Wednesday, August 14, 2024, at 8:30am Eastern Time to present the Company’s results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference ID 13747542. The call will also be webcast live on the Internet at:

https://viavid.webcasts.com/starthere.jsp?ei=1678713&tp_key=b3f21d48c3.

Non-IFRS financial measures

We present EBITDA and adjusted EBITDA because we use these non-IFRS financial measures to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes these non-IFRS financial measures are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company’s core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA is defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, whereas adjusted EBITDA is the EBITDA plus non-cash share-based compensation expenses and certain other costs.

For the projected 2024 adjusted EBITDA information presented herein, the Company is unable to provide a reconciliation of this forward measure to the most comparable IFRS financial measure because the information for these measures is dependent on future events, many of which are outside of the Company’s control. Additionally, estimating such forward-looking measures and providing a meaningful reconciliation consistent with the Company’s accounting policies for future periods is meaningfully difficult and requires a level of precision that is unavailable for these future periods and cannot be accomplished without unreasonable effort.  Forward-looking non-IFRS measures are estimated in a manner consistent with the relevant definitions and assumptions noted in the Company’s adjusted EBITDA for historical periods.

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM®, KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KARAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) our expectation for a cadence of financial results in the second half of 2024 consistent with those achieved in the first six months of the year, 2) full-year revenue guidance to be $158 million-$162 million and adjusted EBITDA to be between $28 million-$32 million, 3) continuing to pursue compelling new business development opportunities, leveraging our financial strength and to support continued growth at double-digit rates beyond 2024, 4) continued patient enrollment in the ongoing pivotal Phase 3 InnovAATe clinical trial, and 5) our expectations to receive FDA feedback to the IND Amendment before the end of 2024, which, if approved, may allow for the acceleration of the InnovAATe program. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, continuation of inbound and outbound international delivery routes, continued demand for Kamada’s products, financial conditions of the Company’s customer, suppliers and services providers, Kamada’s ability to integrate the new product portfolio into its current product portfolio, Kamada’s ability to grow the revenues of its new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

KAMADA LTD.

Condensed Consolidated Interim Statements of Financial Position

KAMADA LTD.

Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income

KAMADA LTD.

Condensed Consolidated Interim Statements of Cash Flows

KAMADA LTD.

Condensed Consolidated Interim Statements of Cash Flows

NON-IFRS MEASURES

Exhibit 99.2

August 2024 Q2 s& H1/2024 Investors Call FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice.

It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical tr ial s. This presentation contains forward - looking statements, which express the current beliefs and expectations of Kamada’s management. Such statements include 2024 financial guidance; 5 - year growth strategy and plans for double digit growth; progression of inhaled AAT clinical study, its benefits and potential market size and potential FDA's feedback during H2/2024; success in being a pioneer in areas of li mit ed treatment alternatives; expansion to new markets, mainly MENA region; growth prospects, product introductions and revenue projections f or KedRAB , Cytogam , Israeli distribution business segment and U.S. plasma segment; success in identify and integrating M&A targets for growth. Th ese statements involve a number of known and unknown risks and uncertainties that could cause Kamada's future results, performance or achievements to differ significantly from the projected results, performances or achievements expressed or implied by such fo rwa rd - looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, risks relat ing to Kamada's ability to successfully develop and commercialize its products and product candidates, progress and results of any clinical t ria ls, introduction of competing products, continued market acceptance of Kamada’s commercial products portfolio, impact of geo - political environment in the middle east, impact of any changes in regulation and legislation that could affect the pharmaceutical industry, difficulty in pr edicting, obtaining or maintaining U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, restrai ns related to third parties’ IP rights and changes in the health policies and structures of various countries, success of M&A strategies, e nvi ronmental risks, changes in the worldwide pharmaceutical industry and other factors that are discussed under the heading “Risk Factors” of Kamada’s 2023 Annual Report on Form 20 - F (filed on March 6, 2024), as well as in Kamada’s recent Forms 6 - K filed with the U.S. Securities and Exchange Commission. This presentation includes certain non - IFRS financial information, which is not intended to be considered in isolation or as a s ubstitute for, or superior to, the financial information prepared and presented in accordance with IFRS. The non - IFRS financial measures may be ca lculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. In accordance wi th the requirement of the SEC regulations a reconciliation of these non - IFRS financial measures to the comparable IFRS measures is incl uded in an appendix to this presentation. Management uses these non - IFRS financial measures for financial and operational decision - making a nd as a means to evaluate period - to - period comparisons. Management believes that these non - IFRS financial measures provide meaningful supplemental information regarding Kamada’s performance and liquidity. Forward - looking statements speak only as of the date they are made, and Kamada undertakes no obligation to update any forward - lo oking statement to reflect the impact of circumstances or events that arise after the date the forward - looking statement was made, exc ept as required by applicable law. 2 KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GROWING GLOBAL COMMERCIAL - STAGE BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 16 % CAGR (from 2021) $ 158 - 162M 2024 Revenues Guidance $ 28 - 32M 2024 Adj.

EBIDTA Guidance 4 Pillars of Growth LEADER IN SPECIALTY PLASMA THERAPIES, FOCUSED ON DISEASES WITH LIMITED TREATMENT ALTERNATIVES $ 56.6 M Cash (Q 2 / 2024 ) 3 Organic Growth M&A Transactions Inhaled AAT Pivotal Study Plasma Collection Centers DELIVERING ON OUR COMMITMENTS 4

KAMADA ’ S ROADMAP FOR ANNUAL DOUBLE - DIGIT GROWTH 5 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories M&A Transactions Support growth through M&A transactions Plasma Collection Centers Each new collection center contributes annual revenues of $8M - $10M Inhaled AAT Phase III pivotal clinical study, targeting a market of over $2B Q 2 – 24 CONTINUING THE GROWTH REVENUE Q 2 - 24 $42.5 Q 2 - 23 $ 37.4 13% NET INCOME Q 2 - 24 $ 4.4 Q 2 - 23 $1.8 144 % GROSS PROFIT Q 2 - 24 $19.0 Q 2 - 23 $ 14.4 31 % Adj.

EBITDA Q 2 - 24 $ 9.1 Q 2 - 23 $6.0 51 % DOUBLE DIGIT INCREASE 6 For reconciliation of Adjusted EBITDA please refer to slide 23 7 REVENUE H 1 - 24 $80.2 H 1 - 23 $ 68.2 18 % NET INCOME H 1 - 24 $ 6.8 H 1 - 23 $0.0 n/a GROSS PROFIT H 1 - 24 $35.7 H 1 - 23 $ 26.3 36 % Adj.

EBITDA H 1 - 24 $ 16.6 H 1 - 23 $9.9 68 % DOUBLE DIGIT INCREASE H 1 – 24 CONTINUING THE GROWTH For reconciliation of Adjusted EBITDA please refer to slide 23 6 18 24 28 - 32 2021 2022 2023 2024 104 129 143 158 – 162 2021 2022 2023 2024 ADJUSTED EBITDA US$M 2024 represents annual guidance 2024 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 16 % CAGR 77 % CAGR H 1 ĔČ Ţ đČƱ š H 1 čē Ţ đēƱ š 8

9 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of HBV recurrence following liver transplants VARIZIG® [Varicella Zoster Immune Globulin (Human)] Post - exposure prophylaxis of varicella in high - risk patients WINRHO® [Rho(D) Immune Globulin (Human)] Treatment of ITP & suppression of Rh isoimmunization (HDN) KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS For Important Safety Information, visit www.Kamada.com GLASSIA® [Alpha 1 - Proteinase Inhibitor (Human)] Augmentation therapy for Alpha - 1 Antitrypsin Deficiency (AATD)

DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious diseases, biosimilar portfolio of 11 product candidates, mainly from Alvotech First biosimilar was launched in Q 1 / 2024 and second product expected to be launched by end of 2024 The other Biosimilar products are expected to be launched through 2028 , upon receipt of regulatory approval Biosimilar portfolio represents the main growth driver with estimated peak annual sales of $ 30 - 34 M 10 11 Exploring strategic business development opportunities to identify potential acquisition or in - licensing Focusing on products synergistic to our existing commercial and/or production activities Strong financial position and proven successful M&A capabilities M&A TRANSACTIONS SEEKING THE NEXT BREAKTHROUGH

12 Currently opening 2 additional centers: Houston, Texas ( H 2 - 24 ) San Antonio, Texas (H 1 - 25 ) Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Average annual revenues of a mature collection center ranges from $ 8 M to $ 10 M KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment.

Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the airways Studied in more than 200 individuals to date, with an established safety profile Only 1 / 8 th of the IV AAT dosing, more cost - effective; favorable market access landscape STUDY D ESIGN EXPECTED ADVANTAGES Ɗ čŃč Ɗ randomization; 9 active sites; ~ 45 % of patients enrolled to date; Open Label Extension (OLE) initiated Mid 2024 Inhaled AAT ĔČ mg Ɗ once Ɗ daily o r Ɗ placebo Ɗ during Ɗ two Ɗ years of Ɗ treatment Primary Ɗ Endpoint: Lung Ɗ function - FEV č Secondary Ɗ Endpoints Ń Lung Ɗ density - CT Ɗ densitometry Ɗ and Ɗ other Ɗ disease Ɗ severity Ɗ parameters 13 POTENTIAL TRANSFORMATIVE TREATMENT IN AATD - RELATED LUNG DISEASE $ 2 Billion A substantial market opportunity ( 2028 ) Filed an IND amendment with revised statistical analysis plan and study protocol, expecting FDA feedback during H 2 / 2024 FDA recently reconfirmed overall study design, endorsed positive safety data to date, and expressed willingness to potentially accept a P< 0.1 alpha level in evaluating the trial ’ s efficacy primary endpoint INHALED AAT PHASE 3 PIVOTAL STUDY Global, double - blind, randomized, placebo - controlled pivotal Phase 3 clinical trial testing the safety and efficacy of inhaled AAT in patients with AATD.

Study design meets FDA and EMA ’ s requirements Source: CantorFizgerald, JAN 11 2024 14

15 US $ M H1/24 H1/23 Q2/24 Q2/23 FY 2023 DETAILS PROPRIETARY 72.9 55.0 39.1 30.9 115.5 Driven by two key growth drivers, KEDRAB® & CYTOGAM® DISTRIBUTION 7.3 13.2 3.3 6.5 27.1 TOTAL REVENUES 80.2 68.2 42.5 37.4 142.5 18% YoY increase; H1 revenues - 50% of mid - point annual guidance GROSS PROFIT 35.7 26.3 19.0 14.4 55.5 GROSS MARGIN 45% 39% 45% 39% 39% 6 basis point increase YoY OPEX (26.0) (23.4) (13.3) (11.8) (45.4) NET PROFIT 6.8 0.0 4.4 1.8 8.3 Adjusted EBITDA 16.6 9.9 9.1 6.0 24.1 68% YoY increase; 21% of revenues & 55% of mid - point annual guidance CASH 56.5 21.8 55.6 TOTAL ASSETS 351.0 314.4 354.9 Including acquisition related intangible assets ($133M @ June 24) BANK LOAN 0.0 15.2 0.0 5 - year term loan paid down in full during Q3 - 23 LEASE LIABILITIES 8.6 6.0 8.8 Increase associated with new plasma collection centers in the U.S.

CONTINGENT LIABILITIES 63.9 80.6 68.2 Acquisition related contingent consideration EQUITY 251.2 176.8 244.0 Increase mainly due to a $60M private placement with FIMI NET DEBT (15.9) (80.1) ( 21.4 ) Contingent and lease liabilities net of available cash Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses STRONG H 1 2024 FINANCIAL RESULTS 16 NON - IFRS MEASURES – ADJUSTED EBITDA US $ M H 1 / 24 H1/23 Q 2 / 24 Q2/23 2023 NET PROFIT 6.8 0.0 4.4 1.8 8.3 TAXES ON INCOME 0.1 0.1 0.1 0.1 0.1 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 3.6 2.1 1.7 0.3 1.0 OTHER FINANCIAL EXPENSE, NET ( 0.8 ) 0.7 ( 0.6 ) 0.4 0.7 AMORTIZATION OF ACQUISITION RELATED INTANGIBLE ASSETS 3.5 3.5 1.8 1.8 7.1 OTHER DEPRECIATION AND AMORTIZATION EXPENSES 2.9 2.8 1.5 1.4 5.7 NON - CASH SHARE - BASED COMPENSATION EXPENSES 0.5 0.6 0.2 0.2 1.3 ADJUSTED EBITDA 16.6 9.9 9.1 6.0 24.1 Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA – SIGNIFICANT UPSIDE POTENTIAL 6 FDA - Approved Products 16 % CAGR (from 2021 ) $ 158 - 162 M 2024 Revenues Guidance $28 - 32M 2024 Adj.

EBIDTA Guidance 4 Pillars of Growth $ 56.6 M Cash (Q 2 / 2024 ) DELIVERING ON OUR COMMITMENTS 17 Organic Growth M&A Transactions Inhaled AAT Pivotal Study Plasma Collection Centers KAMADA LTD.

THANK YOU www.kamada.com